Open company graph database — free web & API
Login

SymBio Pharmaceuticals Inc.

シンバイオ製薬株式会社SymBio Pharmaceuticals LimitedAlias
Ticker
Listed market
TYO
Country
Japan
Employees (non-consolidated)
101
Related companies
1
§01

Basic information

BASIC
Head office
7th Floor, Toranomon Towers Office, 1-28 Toranomon 4-chome, Minato-ku, Tokyo 105-0001, Japan
Chief executive
Fumiki Yoshida
Capital
19,244,128,000  (192 100 million)
Employees (non-consolidated)
101 people
Employees (consolidated)
Start date
2005-03-25
End date
§02

Websites

1 DOMAINS
§03

Business

2
Independent drug discovery businessCollaborative research with academia
§04

Related companies

1 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
SymBio Pharma USA, Inc.
Group
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

55 EVENTS

SymBio Pharmaceuticals Limited established at Nishi-Shimbashi, Minato-ku, TokyoSources

SymBio Pharmaceuticals Co., Ltd. established in Nishi-Shimbashi, Minato-ku, Tokyo.Sources

Head office relocates to Shimbashi, Minato-ku, TokyoSources

Head office moved to Shimbashi, Minato-ku, Tokyo.Sources

License Agreement finalized with Astellas Pharma GmbH for SyB L-0501 (bendamustine) development & commercialization rights in JapanSources

Entered into a license agreement with Astel Pharma (Germany) for exclusive development and sale of the anticancer agent 'Bendamustine Hydrochloride' in Japan.Sources

Manufacturer's License (packaging, labeling and storage) obtained from Tokyo Metropolitan GovernmentSources

Obtained a permit from the Tokyo Metropolitan Government for pharmaceutical manufacturing (packaging, labeling, storage) (Permit No.: 13AZ200010).Sources

License Agreement finalized with Astellas Deutschland GmbH for SyB L-0501 (bendamustine) development & commercialization rights in China (HK), Taiwan, Korea and SingaporeSources

Entered into a license agreement with Astel Dichtlants (Germany) for exclusive development and sale of the anticancer agent 'SyB L-0501' in China, Korea, Taiwan, and Singapore.Sources

License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in JapanSources

Entered into a license agreement with Eisai Co., Ltd. regarding the anticancer agent 'SyB L-0501'.Sources

SymBio Pharmaceuticals concludes Sublicense Agreement with Cephalon, Inc. for development and commercialization rights of bendamustine hydrochloride in China (HK)Sources

Entered into a sublicense agreement with Cefalon Inc. (USA) granting development and commercialization rights for the anticancer agent 'SyB L-0501' in China.Sources

License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in Korea and SingaporeSources

Entered into a license agreement with Eisai Co., Ltd. for the anticancer agent 'SyB L-0501' targeting Korea and Singapore.Sources

Received Domestic Manufacturing and Marketing Approval for Anticancer Agent TREAKISYMSources

Obtained domestic manufacturing and sales approval for the anticancer agent 'TREAKISYM : ® :'.Sources

Launched domestic sales of anticancer agent TREAKISYMSources

Commenced domestic sales of the anticancer agent 'TREAKISYM : ® :'.Sources

Held a press conference for the establishment of Symbio Pharmaceutical Co., Ltd.Sources

Onconova and SymBio Pharmaceuticals complete License Agreement for SyB L-1101/SyB C-1101Sources

Entered into a license agreement with Oncova Inc. (USA) regarding the anticancer agents 'SyB L-1101/SyB C-1101'.Sources

Listed on Osaka Securities Exchange JASDAQ Growth MarketSources

Listed on the Osaka Stock Exchange JASDAQ Growth market.Sources

Head office relocates to Toranomon, Minato-ku, TokyoSources

Head office moved to Toranomon, Minato-ku, Tokyo.Sources

SymBio Pharma USA, Inc. established at Menlo Park, California, USASources

SymBio Pharma USA, Inc. (SymBio Pharma USA Inc.) established in Menlo Park, California, USA.Sources

Established SymBio Pharma USA, Inc. in Menlo Park, California, USA.Sources

Approval for Domestic Manufacturing and Marketing of Anticancer Agent TREAKISYM for Additional Indication of Chronic Lymphocytic LeukemiaSources

Obtained domestic manufacturing and sales approval for the additional efficacy of the anticancer agent 'TREAKISYM : ® :' against chronic lymphocytic leukemia.Sources

SymBio Pharmaceuticals announces the NDA approval of TREAKISYM (bendamustine) for the additional indication of First-line Treatment of Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma in JapanSources

Obtained domestic manufacturing and sales approval for the additional efficacy of the anticancer agent Treaxin® for untreated low-grade non-Hodgkin lymphoma and mantle cell lymphoma.Sources

Eagle Pharmaceuticals (NASDAQ: EGRX) and SymBio Pharmaceuticals completed License Agreement for bendamustine liquid formulations (RTD Injection and RI Injection) development & commercialization rights in Japan *RTD: Ready-to-dilute, RI: Rapid InfusionSources

Entered an exclusive licensing agreement with Eagle Pharmaceuticals (USA) for the development and commercialization of Bendamustine liquid formulations (RTD and RI) in Japan.Sources

TREAKISYM (bendamustine) has been newly included as a standard-of-care option in the Guidelines for Tumors of Hematopoietic and Lymphoid Tissues 2018Sources

Treaxin® was newly included as a standard treatment option in the 2018 edition of the Hematologic Tumor Treatment Guidelines.Sources

Treaxin® was newly included as a standard treatment option in the 2018 edition of the Hematologic Tumor Treatment Guidelines.Sources

September 2019: Chimerix (USA) and anti-viral drug 'Brinshidohobiru' (excluding smallpox) entered into an exclusive global license agreement for development, sales, and manufacturingSources

Entered an exclusive global licensing agreement with Chimerix (USA) for the development, sale, and manufacture of the antiviral drug Brinshidobiv (excluding smallpox).Sources

SymBio Pharmaceuticals receives approval of TREAKISYM Ready-To-Dilute (RTD) formulationSources

Obtained approval for the manufacturing and sales of Treaxin® liquid formulation (RTD).Sources

Commencement of in-house sales of the anti-cancer agent TREAKISYM : ®Sources

Commenced in-house sales of the anticancer agent Treaxin®.Sources

Market Launch of TREAKISYM : ® : Ready-To-Dilute (RTD) FormulationSources

Released Treaxin® liquid formulation (RTD).Sources

SymBio Pharmaceuticals receives approval of TREAKISYM : ® : (bendamustine) in combination with rituximab, and in combination with rituximab and polatuzumab vedotin for relapsed or refractory diffuse large B-cell lymphomaSources

Obtained approval for the combination therapy of Treaxin® and rituximab for relapsed or refractory diffuse large B-cell lymphoma, and also approval for the combination therapy of Treaxin®, rituximab, and polatuzumab vedotin.Sources

SymBio Pharmaceuticals receives approval of TREAKISYM : ® : Ready-To-Dilute (RTD) Formulation in combination with rituximab ,and in combination with rituximab and polatuzumab vedotin for relapsed or refractory diffuse large B-cell lymphomaSources

Obtained approval for the combination therapy of Treaxin® liquid formulation (RTD) and rituximab for relapsed or refractory diffuse large B-cell lymphoma, and also approval for the combination therapy of Treaxin® liquid formulation (RTD), rituximab, and polatuzumab vedotin.Sources

SymBio Pharmaceuticals receives approval of 10-minute Rapid Infusion (RI) administration of the TREAKISYM : ® : Liquid FormulationSources

Obtained approval for the Treaxin® liquid formulation (RI administration, 10-minute infusion).Sources

Head office relocates within Toranomon, Minato-ku, TokyoSources

Relocated headquarters to Toranomon, Minato-ku, Tokyo.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information1010401057034
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
シンバイオ製薬株式会社
Trade name (kana)
シンバイオセイヤク
Name in English
Corporation type
301
Address
〒105-0001 東京都港区虎ノ門4丁目1番28号
Postal code
1050001
Prefecture code
13
City code
103
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2023-12-04
Change date
2023-12-01
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
1298574
METI gBizINFO1010401057034
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
1010401057034
Trade name
シンバイオ製薬株式会社
Trade name (kana)
シンバイオセイヤク
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都港区虎ノ門4丁目1番28号
Postal code
1050001
Prefecture
東京都
Prefecture code
13
City or district
港区
City code
103
Street address
虎ノ門4丁目1番28号
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
代表取締役社長兼CEO    吉田  文紀
Capital
19244128000
Employees
150
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
E:製造業
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2023-12-04
Key information
1010401057034
§09

Sources & updates

SOURCES
↑